The Critical Path Institute
CAGE Code: 35JZ0
NCAGE Code: 35JZ0
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 175893135
Summary
The Critical Path Institute is an Active Commercial Supplier with the Cage Code 35JZ0 and is tracked by Dun & Bradstreet under DUNS Number 175893135..
Address
1840 E River Rd
Suite 100
Tucson AZ 85718-5893
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Stephanie Egurrola Rv Awards Emc Industrial Supply Inc Westmed, Inc. Acra Systems Engineering Inc Slabaugh Joyce People Power Llc Video Apartment Guide Computer Communication Intl International Computers Of The Arizona Restaurant Supply Inc Mellex Software Solutions Promotion Products Group Glendale Graphics Advanced Protection Systems Burns Design Enterprises Landeco Intertec Southwest Llc Tellez Daniel Painting Co Lbj Inc
Frequently Asked Questions (FAQ) for CAGE 35JZ0
- What is CAGE Code 35JZ0?
- 35JZ0 is the unique identifier used by NATO Organizations to reference the physical entity known as The Critical Path Institute located at 1840 E River Rd, Suite 100, Tucson AZ 85718-5893, United States.
- Who is CAGE Code 35JZ0?
- 35JZ0 refers to The Critical Path Institute located at 1840 E River Rd, Suite 100, Tucson AZ 85718-5893, United States.
- Where is CAGE Code 35JZ0 Located?
- CAGE Code 35JZ0 is located in Tucson, AZ, USA.
Contracting History for CAGE 35JZ0 Most Recent 25 Records
- 75F40122C00196
- The Purpose Of This Modification Is To Extending Option Period Of Performance End Date From 01/28/2024 To 05/28/2024.
- 1 Sep 2023
- The Purpose Of This Modification Is To Extending Option Period Of Performance End Date From 01/28/2024 To 05/28/2024.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,756,265.63
- Department Of Health And Human Services (Hhs)
- 75F40122C00196
- Baa Eetwp #63: A Standardized Framework To Support Fda Qualification Of Complex In Vitro Models For Use In Regulatory Submissions.
- 26 Sep 2022
- Baa Eetwp #63: A Standardized Framework To Support Fda Qualification Of Complex In Vitro Models For Use In Regulatory Submissions.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $937,737.91
- Department Of Health And Human Services (Hhs)
- 75F40122C00196
- The Purpose Of This Modification Is To Revise Budget To Support Scientific Conferences.
- 8 May 2023
- The Purpose Of This Modification Is To Revise Budget To Support Scientific Conferences.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,032,744.14
- Department Of Health And Human Services (Hhs)
- 75F40122C00196
- Baa Eetwp #63: A Standardized Framework To Support Fda Qualification Of Complex In Vitro Models For Use In Regulatory Submissions.
- 25 Apr 2023
- Baa Eetwp #63: A Standardized Framework To Support Fda Qualification Of Complex In Vitro Models For Use In Regulatory Submissions.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,032,744.14
- Department Of Health And Human Services (Hhs)
- 75F40120C00199
- Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- 13 Jul 2021
- Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $759,694.00
- Department Of Health And Human Services (Hhs)
- 75F40120C00199
- Eo14042 Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- 2 Feb 2023
- Eo14042 Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,128,848.00
- Department Of Health And Human Services (Hhs)
- 75F40120C00199
- Eo14042 Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- 17 Nov 2021
- Eo14042 Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $759,694.00
- Department Of Health And Human Services (Hhs)
- 75F40120C00199
- Eo14042 Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- 14 Oct 2022
- Eo14042 Pmwp 108 Model-Informed Drug Development (Midd) In The Evaluation And Development Of Neurological Drug Products
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,128,848.00
- Department Of Health And Human Services (Hhs)
- 75F40119C10135
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- 14 Mar 2023
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $759,324.67
- Department Of Health And Human Services (Hhs)
- 75F40119C10135
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- 10 Nov 2022
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,757,771.00
- Department Of Health And Human Services (Hhs)
- 75F40119C10135
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- 27 Aug 2022
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,757,771.00
- Department Of Health And Human Services (Hhs)
- 75F40119C10135
- Eo14042 Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- 22 Nov 2021
- Eo14042 Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,757,771.00
- Department Of Health And Human Services (Hhs)
- 75F40119C10135
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- 20 Apr 2023
- Broad Agency Announcement (Baa) Contract -- Developing Novel Clinical Outcome Assessments For Pediatric Asthma To Facilitate Innovative Patient-Focused Drug Development And Aid Regulatory Decision Making
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $2,757,771.00
- Department Of Health And Human Services (Hhs)
- 75F40118C10184
- Igf::Ot::Igf - Developing Novel Kidney Transplant Drug Development Tools To Enhance Regulatory Decision Making And Enable Innovation In Medical Product Development
- 19 Sep 2018
- Igf::Ot::Igf - Developing Novel Kidney Transplant Drug Development Tools To Enhance Regulatory Decision Making And Enable Innovation In Medical Product Development
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,594,872.00
- Department Of Health And Human Services (Hhs)
- 75F40118C10184
- Executive Order 14042, Ensuring Adequate Covid Safety Protocols For Federal Contractors
- 9 Nov 2021
- Executive Order 14042, Ensuring Adequate Covid Safety Protocols For Federal Contractors
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,594,872.00
- Department Of Health And Human Services (Hhs)
- 75F40118C10184
- Extend The Current Period Of Performance To December 30, 2022
- 25 Aug 2022
- Extend The Current Period Of Performance To December 30, 2022
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,594,872.00
- Department Of Health And Human Services (Hhs)
- 75F40118C10184
- Developing Novel Kidney Transplant Drug Development Tools To Enhance Regulatory Decision Making And Enable Innovation In Medical Product Development
- 16 Aug 2021
- Developing Novel Kidney Transplant Drug Development Tools To Enhance Regulatory Decision Making And Enable Innovation In Medical Product Development
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,594,872.00
- Department Of Health And Human Services (Hhs)
- 75F40118C10184
- Ensuring Adequate Covid Safety Protocols For Federal Contractors
- 24 Jan 2022
- Ensuring Adequate Covid Safety Protocols For Federal Contractors
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $1,594,872.00
- Department Of Health And Human Services (Hhs)